Your session is about to expire
← Back to Search
AL002 for Alzheimer's Disease
Study Summary
This trial evaluates how safe, tolerable and effective a new Alzheimer's treatment is over time.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am considered unable to give consent for medical procedures.
- Group 1: AL002 Dose 1
- Group 2: AL002 Dose 2
- Group 3: AL002 Dose 3
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are participants currently being accepted for enrollment in this study?
"The study, which was initially posted on April 1st 2023 and subsequently edited on February 15th of the same year, is currently in need of participants. This information can be found documented on clinicaltrials.gov."
Does this clinical trial accept participants aged 70 and above?
"Meeting the stipulated criteria for inclusion, the bottom limit of age to be allowed in this research project is 50 and its upper end stands at 85."
How hazardous is AL002 Dose 1 to human health?
"Given that this is an exploratory Phase 2 trial, AL002 Dose 1 was adjudged to have a safety rating of 2. This score reflects the presence of some data regarding its security but none confirming efficacy."
Do I possess the necessary qualifications to enroll in this investigation?
"This trial seeks patients with Alzheimer's disease between the ages of fifty and eighty-five. Approximately 190 participants are needed to meet enrollment goals."
What is the cap on the amount of people participating in this trial?
"To progress this clinical trial, 190 volunteers that meet the inclusion criteria must partake. These individuals can apply at Advanced Clinical Institute in Neptune (NJ) or Summit Research Network in Portland (OR)."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger